UAB CF Research and Translation Core Center

UAB CF 研究与翻译核心中心

• 批准号: 10468801
• 负责人: David M. Bedwell
• 金额: $ 111.37万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2023-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10468801
• 关键词: Achievement; Address; American Lung Association; Animal Model; Animals; Anti-Inflammatory Agents; Award; Bacteriophages; Basic Science; Biological Assay; Biological Models; Biomedical Research; Cell model; Cells; Cellular Assay; Clinical; Clinical Sciences; Collection; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Disease; Drug Industry; Education; Educational workshop; Elements; Engineering; Environment; Enzymes; Evaluation; Exhibits; Faculty; Fostering; Foundations; Functional disorder; Funding; Future; Generations; Goals; Growth; Host Defense; Human; Image; Infection; Inflammation; Institution; Interdisciplinary Communication; Interdisciplinary Study; International; Intervention; Investigation; Investigational Therapies; Knowledge; Laboratories; Leadership; Measures; Mediating; Mentorship; Microbial Biofilms; Modeling; Monitor; Mucolytics; Mucous body substance; Nonsense Mutation; Nonsense-Mediated Decay; Outcome Measure; Output; Oxidases; Pathogenesis; Pathway interactions; Patients; Peer Review Grants; Pilot Projects; Population; Positioning Attribute; Pseudomonas aeruginosa; Rattus; Reagent; Research; Research Personnel; Research Support; Resources; Respiratory Tract Infections; Retirement; Role; Science; Scientific Advances and Accomplishments; Senior Scientist; Series; Services; Site; Structure; System; Techniques; Testing; Therapeutic; Therapeutic Intervention; Training; Translating; Translational Research; Translations; United States; United States National Institutes of Health; Universities; VX-770; Work; age related; base; body system; career development; clinical center; clinical translation; cohesion; collaborative environment; cystic fibrosis infection; cystic fibrosis mucus; cystic fibrosis patients; design; drug discovery; effectiveness research; experience; improved; in vivo imaging; innovation; invention; member; multidisciplinary; mutant; next generation; novel; novel therapeutics; prevent; programs; protein crosslink; ranpirnase; repository; research and development; success; synergism; therapeutic evaluation; therapy development; tool; training opportunity; translational scientist; viscoelasticity

PROJECT SUMMARY/ABSTRACT The UAB P30 Research and Translation Core Center consolidates a large number of externally funded cystic fibrosis (CF) research programs on our campus, building an innovative environment to pursue, advance, and train in CF-related science. During the last funding period, the P30 made robust and important contributions to multiple UAB laboratories of our Research Base of over 70 investigators pursuing research relevant to CFTR modulation, CF pathogenesis, and therapeutic translation. By virtue of the NIH Center, translational research at our Institution has greatly accelerated in the past five years, as has the breadth of investigators. The richness of CF basic science at UAB has grown in parallel with this translational expansion, providing numerous opportunities to exploit in the next funding period, and we have modified the structure of the Center accordingly to take advantage of these opportunities. The P30 Center has allowed investigators at UAB and collaborating sites to improve understanding of CF disease mechanism and has furnished novel opportunities to aggressively apply this information towards experimental therapeutics. This NIH Center includes three Biomedical Research Cores that help to organize efforts of CF faculty towards the common and essential goal of helping individuals with CF and to train the next generation of CF leaders. The Cores include: Core A: Cell Model and Assay Core (B Woodworth and GM Solomon, Co-PIs); Core B: Animal Models Core (DM Bedwell, PI); and Core C: Clinical and Translational Core (SM Rowe and A Gaggar, Co-PIs). Each Core provides leading-edge assays, specialized reagents and techniques, and valued expertise. The P30 has also engaged new investigators through a Pilot and Feasibility mechanism integral to Center vitality and has a tight integration with the UAB Center for Clinical and Translational Science, enabling a robust training environment. In addition to providing a platform from which junior and senior scientists are brought into the field, Pilot Projects serve as a means of rapidly testing exciting advances, particularly from the perspective of clinical translation. Two Pilot and Feasibility Projects are proposed: Project 1: V Thannickal, PI. “Mucus Viscoelasticity is Mediated by Oxidase Enzymes through Oxidative Protein Crosslinking”; and Project 2: J Campos-Gomez, PI. “Engineered PF Phage to Treat Pseudomonas aeruginosa Biofilm Infections”, capitalizing on the next era of innovative opportunities to transform the disease. Through these scientific initiatives, the P30 has added value to a collaborative environment for CF research at our Institution, and is well-positioned to continue in this capacity in the future, with a major focus on therapeutic translation.

项目总结/文摘